Clazakizumab to Lower Inflammation in Adults at Risk of Heart Disease Events
Tests clazakizumab against placebo for lowering inflammation in adults at heart risk.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Altamonte Springs, Buffalo, Cincinnati, Cutler Bay, Cypress, Dearborn, Foxborough, Glendora, Houston, Huntsville, Indianapolis, Kingwood, Las Vegas, Lombard, Maitland, Manassas, McKinney, North Charleston, Ogden, Olive Branch, Orlando, Reston, The Bronx, Tucson, West Chester, Woodstock, and Yardley, United StatesSee the 30 sitesAlso in 3 other countries, 16 sites
- Trial code
- Registry title
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 27 Aug 2026
- Expected to end
- Oct 2027
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Clazakizumab
- Placebo
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with raised hsCRP, a blood marker of inflammation, who have heart and blood vessel disease or are at higher risk of it.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- At least one of these: established atherosclerotic cardiovascular disease, obesity (BMI ≥30 kg/m2), type 2 diabetes, hypertension, or chronic kidney disease Grade 3 or 4.
- Earlier treatment
- Cannot have used colchicine within 14 days, systemic corticosteroids within 14 days, or immunosuppressive or immunomodulatory drugs (including other anti-IL-6 biologics) within specified windows. Cannot be on chronic NSAIDs.
- Biomarker or test result
- hsCRP ≥2 mg/L and ≤15 mg/L at screening.
Main reasons for not taking part
- Acute cardiovascular event or acute decompensated heart failure hospitalization within 60 days before screening
- New York Heart Association Class III or IV heart failure
- Type 1 diabetes, or type 2 diabetes with Hemoglobin A1c ≥9.0% (75 mmol/mol)
- Dialysis, kidney transplant, or eGFR <15 mL/min/1.73 m²
- Active tuberculosis, hepatitis B or C, or a weakened immune system such as HIV infection
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- hsCRP ≥2 mg/L and ≤15 mg/L at screening
- At least one of the following chronic conditions:; Established atherosclerotic cardiovascular disease (ASCVD); Obesity (body mass index (BMI) ≥30 kg/m2); Type 2 diabetes; Hypertension; Chronic kidney disease Grade 3 or 4
Who cannot take part
- Acute cardiovascular event within 60 days prior to screening
- Acute decompensated heart failure hospitalization within 60 days prior to screening
- Planned coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or major surgery at the time of randomization
- Dialysis or acute kidney injury within 60 days prior to screening
- Serious, opportunistic, chronic, or recurrent infection requiring treatment within 12 weeks prior to screening
- History of peptic ulcer disease or gastrointestinal ulceration within 12 months prior to screening
- Use of colchicine within 14 days prior to screening or anticipated need during the study
- Use of immunosuppressive or immunomodulatory agents, including other biologic anti-IL-6 therapies, within specified windows prior to screening
- Use of systemic corticosteroids within 14 days prior to screening
- Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs)
- New York Heart Association Class III or IV heart failure
- Uncontrolled hypertension at screening (systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg)
- Type 1 diabetes
- Congenital/hereditary kidney disease, polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody-associated vasculitis
- Active tuberculosis, untreated latent tuberculosis, or known hepatitis B or hepatitis C infection
- Significant active autoimmune disease
- Suspected or confirmed immunocompromised state (e.g., HIV infection)
- History of symptomatic diverticular disease (diverticulitis), gastrointestinal perforation, or major gastrointestinal surgery
- Mechanical heart valve prosthesis requiring chronic vitamin K antagonist anticoagulation
- Type 2 diabetes with Hemoglobin A1c ≥9.0% (86 mmol/mol) at screening
- Nephrotic syndrome, estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m², or history of kidney transplant
Where in United States
Also in 3 other countries, 16 sites
- Omega Research OrlandoAltamonte Springs, United StatesContact: Kwabena Ayesu (principal investigator)Taking people
- Rochester Clinical Research - BuffaloBuffalo, United StatesContact: Richard Carlson (principal investigator)Taking people
- Velocity Clinical Research, Cincinnati, SpringdaleCincinnati, United StatesContact: Charles Eger (principal investigator)Taking people
- American Research InstituteCutler Bay, United StatesContact: Manuel Garcia Estrada (principal investigator)Taking people
- Horizon Clinical Research GroupCypress, United StatesContact: Fadi Alameddine (principal investigator)Taking people
- Revival Research Institute, LLCDearborn, United StatesContact: Qaiser Shafiq (principal investigator)Taking people
- K2 Medical Research - FoxboroughFoxborough, United StatesContact: Daniel Sacchetti (principal investigator)Taking people
- Thrive Clinical Research GroupGlendora, United StatesContact: Fahed Bitar (principal investigator)Taking people
- Cardiovascular Specialists of WillowbrookHouston, United StatesContact: Aditya Samal (principal investigator)Taking people
- Heart Center Research, LLCHuntsville, United StatesContact: Walter Haught (principal investigator)Taking people
- Franciscan Physician Network, Indiana Heart PhysiciansIndianapolis, United StatesContact: Anthony Bashall (principal investigator)Taking people
- Texas Cardiology Associates of HoustonKingwood, United StatesContact: Robert Salazar (principal investigator)Taking people
- Excel Clinical Research, LLCLas Vegas, United StatesContact: Robby Quintos (principal investigator)Taking people
- Palm Research Center TenayaLas Vegas, United StatesContact: Samer Nakhle (principal investigator)Taking people
- Accellacare - DuPageLombard, United StatesContact: Yoko Momoyama (principal investigator)Not yet recruiting
- K2 Medical Research - MaitlandMaitland, United StatesContact: Neel Patel (principal investigator)Taking people
- Carient Heart & Vascular - ManassasManassas, United StatesContact: Hamid Taheri (principal investigator)Taking people
- Revival Research Institute, LLCMcKinney, United StatesContact: Asad Karim (principal investigator)Taking people
- Texas Institute of Cardiology PAMcKinney, United StatesContact: Faisal Wahid (principal investigator)Taking people
- Monroe Biomedical Research - CharlestonNorth Charleston, United StatesContact: Gregory Feldman (principal investigator)Taking people
- Ogden Clinic - Canyon ViewOgden, United StatesContact: Stephen Bruce (principal investigator)Taking people
- Olive Branch Family Medical CenterOlive Branch, United StatesContact: Randall Huling (principal investigator)Taking people
- Florida Institute For Clinical Research, LLCOrlando, United StatesContact: Humberto Cruz (principal investigator)Taking people
- Carient Heart and Vascular LLC-RestonReston, United StatesContact: Adeeb Aghdassi (principal investigator)Taking people
- CHEAR Center LLCThe Bronx, United StatesContact: David Bernard (principal investigator)Taking people
- Eclipse Clinical ResearchTucson, United StatesContact: Eve Shapiro (principal investigator)Taking people
- Pima HeartTucson, United StatesContact: Ajay Tuli (principal investigator)Taking people
- Suburban Research AssociatesWest Chester, United StatesContact: Omer Abdullah (principal investigator)Taking people
- North Georgia Clinical ResearchWoodstock, United StatesContact: Bram Wieskopf (principal investigator)Taking people
- Cardiology Consultants of Philadelphia YardleyYardley, United StatesContact: Paul Grena (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event.
Read full original descriptionShow less
Participation in the study will last about 9 months.
The 4 groups in the trial
- Clazakizumab Dose 1Treatment being tested
Participants will receive clazakizumab subcutaneously (SC)
Treatment: Clazakizumab
- Clazakizumab Dose 2Treatment being tested
Participants will receive clazakizumab SC
Treatment: Clazakizumab
- Clazakizumab Dose 3Treatment being tested
Participants will receive clazakizumab SC
Treatment: Clazakizumab
- PlaceboPlacebo, for comparison
Participants will receive placebo SC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Clazakizumab in Reducing hsCRP in Adults With Elevated hsCRP and Established ASCVD or at Increased Risk for ASCVD Events
- Plain-language title
- Clazakizumab to Lower Inflammation in Adults at Risk of Heart Disease EventsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 3 November 2026